{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:10:21Z","timestamp":1760782221619},"reference-count":12,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6750,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1023\/a:1011118004629","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T11:26:45Z","timestamp":1040642805000},"page":"1011-1013","source":"Crossref","is-referenced-by-count":4,"title":["A randomized trial of four cycles of adjuvant AC (adriamycin + cyclophosphamide) \u00b1 two cycles of EP (etoposide + cisplatin) in node positive patients with breast cancer"],"prefix":"10.1016","volume":"12","author":[{"given":"F.","family":"I\u00e7li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Akbulut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Din\u00e7ol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Onur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Demirkazik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"\u00c7am","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"\u00c7ay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"\u00dcner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Erekul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1011118004629_bb0010","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1200\/JCO.1990.8.9.1483","volume":"8","author":"Fisher","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011118004629_bb0015","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.1999.17.11.3374","article-title":"Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer Findings from National Surgical Adjuvant Breast and Bowel Project B-25","volume":"17","author":"Fisher","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011118004629_bb0020","first-page":"390A","article-title":"Improved DFS and OS from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node positive primary breast cancer","author":"Henderson","year":"1998","journal-title":"ASCO Proc"},{"key":"10.1023\/A:1011118004629_bb0025","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.1995.03520310040027","article-title":"Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes Ten-year results","volume":"273","author":"Bonadonna","year":"1995","journal-title":"JAMA"},{"key":"10.1023\/A:1011118004629_bb0030","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.1991.9.4.664","article-title":"Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma. A prospective randomized trial of the Italian Oncology Group for Clinical Research","volume":"9","author":"Cocconi","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011118004629_bb0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/jso.2930500411","article-title":"Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer","volume":"50","author":"I\u00e7li","year":"1992","journal-title":"J Surg Oncol"},{"key":"10.1023\/A:1011118004629_bb0040","first-page":"147a","article-title":"Cisplatin and oral etoposide (PEO) in heavily pretreated patients with advanced breast cancer patients","volume":"17","author":"I\u00e7ji","year":"1998","journal-title":"ASCO Proc"},{"key":"10.1023\/A:1011118004629_bb0045","series-title":"WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No 48","author":"World Health Organization","year":"1979"},{"key":"10.1023\/A:1011118004629_bb0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparanietnc estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Satat Assoc"},{"key":"10.1023\/A:1011118004629_bb0055","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer An overview of the randomized trials. Early Breast Cancer Trialists\u2019 Collaborative Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1023\/A:1011118004629_bb0060","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/BF01908240","article-title":"Dose-intensive treatment of breast cancer supported by granulocyte-macrophage colony-stimulating factor (GM-CSF)","volume":"20","author":"Neidhart","year":"1991","journal-title":"Breast Cancer Res Treat"},{"key":"10.1023\/A:1011118004629_bb0065","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/1097-0142(19930715)72:2<587::AID-CNCR2820720242>3.0.CO;2-V","article-title":"Severe vascular toxicity associated with cisplatin based chemotherapy","volume":"72","author":"I\u00e7h","year":"1993","journal-title":"Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419541904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419541904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/7\/1011\/19479317\/12-7-1011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:05:32Z","timestamp":1582182332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419541904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["S0923753419541904"],"URL":"https:\/\/doi.org\/10.1023\/a:1011118004629","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}